Information Provided By:
Fly News Breaks for December 6, 2018
CRMD
Dec 6, 2018 | 07:32 EDT
Roth Capital analyst Jerry Isaacson started coverage of CorMedix with a Buy rating and $6 price target. The analyst notes that the company is developing Neutrolin for the prevention of catheter-related blood stream infections in patients with central venous catheters, and believes there is a large market opportunity for Neutrolin in multiple patient populations. CorMedix has Fast-Track designation from the FDA and QIDP designation, leading to 10.5 years of market exclusivity, he adds.
News For CRMD From the Last 2 Days
There are no results for your query CRMD
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.